A Phase III Study of Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents Aged Between 7 and 17 Years with Autism Spectrum Disorder (SIGN 1 Trial): Participant Baseline Characteristics. - Georgoula, Christina; Ferrin, Maite; Pietraszczyk-Kedziora, Bozena; Hervas, Amaia; Marret, Stéphane; Oliveira, Guiomar; Rosier, Antoine; Crutel, Véronique; Besse, Emmanuelle; Severo, Cristina Albarrán; Ravel, Denis; Fuentes, Joaquin (Child Psychiatry & Human Development, 2023)